CMMMY23044 // S2209 // Lipe
Basic Study Information
Purpose:
This phase III trial compares three-drug induction regimens followed by double-or
single-drug maintenance therapy for the treatment of newly diagnosed multiple myeloma
in patients who are not receiving a stem cell transplant and are considered frail
or intermediate-fit based on age, comorbidities, and functional status. Treatment
for multiple myeloma includes initial treatment (induction) which is the first treatment
a patient receives for cancer followed by ongoing treatment (maintenance) which is
given after initial treatment to help keep the cancer from coming back. There are
three combinations of four different drugs being studied. Bortezomib is one of the
drugs that may stop the growth of cancer cells by blocking some of the enzymes needed
for cell growth. Lenalidomide works by helping bone marrow to produce normal blood
cells and killing cancer cells. Anti-inflammatory drugs, such as dexamethasone, lower
the body's immune response and are used with other drugs in the treatment of some
types of cancer. Daratumumab and hyaluronidase-fihj is a monoclonal antibody that
may interfere with the ability of cancer cells to grow and spread. Patients receive
1 of 3 combinations of these drugs for treatment to determine which combination of
study drugs works better to shrink and control multiple myeloma.
Location: University of Rochester
Lead Researcher (Principal Investigator)
Lead Researcher:
Brea Lipe
Study Contact Information
Study Contact: Clinical Trials Office
Study Location: Wilmot Cancer Institute, University of Rochester Medical Center
Study Email: WCICTOResearch@urmc.rochester.edu
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search